RE:RE:RE:Clinics and PharmWhat's your calculation if you have one?
Cloudmd paid 13MM with 4.5M in cash and rest in dilluted shares. Annual ravenue of CP is just under 40MM, but low profit business.
Karen should not sell this, but it's probably done deal. @dartmom is probably closer to the reality and they'll sell CP for 4-5MM cash.. and those 8MM dilluted shares would be $0.
You end up with lower assets, quarterly ravenue will drop to ~28MM from 40MM, and you still have 294Mil. of shares. .. You'll get couple of hundreds of one time divident when Karen sells CP.
I think with two remaining devisions she can sell it. Probably potential buyer is not interested in CP and other two divisions at same time. So they have to look in two tier sale.
We are in recession, and organic growth is story for kids. This thing is dead in the water. The only question is will retail investors leave with nothing, or next to nothing.
Of course, they'll make deal with Hamza and his monkies to leave the board and get another payout.
So, part of payout cash from CP will go to pockets of the board, and leftovers to cute retail investors.